| |
Latest 10 SEC filings (by transaction date) for ZYME within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 2/24 | Apr 2/24 | Gallagher Neil | Direct Ownership | No securities are beneficially owned | Form 3 : Initial Statement of Beneficial Ownership of Securities | ||
Apr 2/24 | Apr 2/24 | Gallagher Neil | Direct Ownership | No securities are beneficially owned | Form 3 : Initial Statement of Beneficial Ownership of Securities | ||
Feb 9/24 | Feb 9/24 | Cesano Alessandra | Direct Ownership | No securities are beneficially owned | Form 3 : Initial Statement of Beneficial Ownership of Securities | ||
Feb 9/24 | Feb 9/24 | Cesano Alessandra | Direct Ownership | No securities are beneficially owned | Form 3 : Initial Statement of Beneficial Ownership of Securities | ||
Feb 9/24 | Feb 8/24 | Cesano Alessandra | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 74,000 | |
Jan 8/24 | Jan 8/24 | Galbraith Kenneth | Direct Ownership | Common Stock | S - Open market or private sale | -5,706 | $11.22 |
Jan 8/24 | Jan 8/24 | Astle Christopher | Direct Ownership | Common Stock | S - Open market or private sale | -1,431 | $11.22 |
Jan 8/24 | Jan 8/24 | Moore Paul Andrew | Direct Ownership | Common Stock | S - Open market or private sale | -2,339 | $11.22 |
Jan 8/24 | Jan 5/24 | Galbraith Kenneth | Direct Ownership | Restricted Stock Unit | A - Grant, award or other under Rule 16b-3(d) | 200,000 | |
Jan 8/24 | Jan 5/24 | Galbraith Kenneth | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 300,000 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for ZYME within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 2/24 | Apr 2/24 | Gallagher Neil | Direct Ownership | No securities are beneficially owned | Form 3 : Initial Statement of Beneficial Ownership of Securities | ||
Apr 2/24 | Apr 2/24 | Gallagher Neil | Direct Ownership | No securities are beneficially owned | Form 3 : Initial Statement of Beneficial Ownership of Securities | ||
Feb 9/24 | Feb 8/24 | Cesano Alessandra | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 74,000 | |
Feb 9/24 | Feb 9/24 | Cesano Alessandra | Direct Ownership | No securities are beneficially owned | Form 3 : Initial Statement of Beneficial Ownership of Securities | ||
Feb 9/24 | Feb 9/24 | Cesano Alessandra | Direct Ownership | No securities are beneficially owned | Form 3 : Initial Statement of Beneficial Ownership of Securities | ||
Jan 8/24 | Jan 5/24 | Galbraith Kenneth | Direct Ownership | Restricted Stock Unit | A - Grant, award or other under Rule 16b-3(d) | 200,000 | |
Jan 8/24 | Jan 5/24 | Galbraith Kenneth | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 300,000 | |
Jan 8/24 | Jan 5/24 | Galbraith Kenneth | Direct Ownership | Restricted Stock Unit | M - Exercise or conversion exempt under rule 16b-3 | -47,666 | |
Jan 8/24 | Jan 8/24 | Galbraith Kenneth | Direct Ownership | Common Stock | S - Open market or private sale | -5,706 | $11.22 |
Jan 8/24 | Jan 5/24 | Galbraith Kenneth | Direct Ownership | Common Stock | S - Open market or private sale | -18,198 | $10.65 |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |
Madrigal Pharmaceuticals (OQ:MDGL) |